Login/Register

GXIPC1 (treating type 1 diabetes by using stem cell new drug)

Taiwan
Introduction
GXIPC1 is an allogeneic adipose-derived stem cells therapy for treating diabetes. In pre-clinical data, GXIPC1 showed therapeutic potential for regulating blood sugar and protecting islets. Currently, GXIPC1 is ongoing in clinical trial I at Vinmec Research Institute of Stem Cell and Gene Technology (VIRISG) in Vietnam.

The phase I trial (NCT05308836) has been approved by the Ministry of Health of Vietnam (MOH) in Vietnam and initiated patient enrollment. Moreover, it is worth to point out that we are the first firm delivering qualified stem cell medicine overseas in Taiwan.
Features / strengths
.Off-the-shelf
.The allogeneic stem cell source is in compliance with the medical regulation
.GXIPC1 is a very first human trial delivering qualified allogeneic stem cell overseas in Taiwan for carrying out clinical trial
.GXIPC1 has been approved by MOH (competent authority) in Vietnam
Specification in detail
Material
Adipose-derived stem cells (ADSCs)
Indication
Type 1 Diabetes
Administration
Intravenous injection
Product Status
Phase I (NCT05308836)
Location
Vietnam

Clients
Vinmec International Hospital

Information
Introduction
GXIPC1 is an allogeneic adipose-derived stem cells therapy for treating diabetes. In pre-clinical data, GXIPC1 showed therapeutic potential for regulating blood sugar and protecting islets. Currently, GXIPC1 is ongoing in clinical trial I at Vinmec Research Institute of Stem Cell and Gene Technology (VIRISG) in Vietnam.

The phase I trial (NCT05308836) has been approved by the Ministry of Health of Vietnam (MOH) in Vietnam and initiated patient enrollment. Moreover, it is worth to point out that we are the first firm delivering qualified stem cell medicine overseas in Taiwan.
Features / strengths
.Off-the-shelf
.The allogeneic stem cell source is in compliance with the medical regulation
.GXIPC1 is a very first human trial delivering qualified allogeneic stem cell overseas in Taiwan for carrying out clinical trial
.GXIPC1 has been approved by MOH (competent authority) in Vietnam
Specification in detail
Material
Adipose-derived stem cells (ADSCs)
Indication
Type 1 Diabetes
Administration
Intravenous injection
Product Status
Phase I (NCT05308836)
Location
Vietnam
Clients
Vinmec International Hospital

GXIPC1 (treating type 1 diabetes by using stem cell new drug)

Taiwan
Gwo Xi Stem Cell Applied Technology Co., Ltd. Other products
Recommended